Multiple Myeloma

Early teclistamab discontinuation after deep response showed PFS comparable to continuous therapy in relapsed/refractory myeloma in the LimiTEC trial.

Teclistamab/daratumumab improved survival outcomes and led to deep MRD-negative responses vs daratumumab-based regimens in relapsed/refractory myeloma.

Triplet therapy with tagraxofusp/azacitidine/venetoclax led to high remission rates and had a safety profile similar to that of tagraxofusp alone in BPDCN.

Talquetamab plus teclistamab produced a high ORR and CR or better rate in relapsed/refracotry multiple myeloma with true extramedullary disease.

Linvoseltamab monotherapy produced responses and was safe in newly diagnosed multiple myeloma.

AZD0120 CAR T therapy shows rapid, deep responses and manageable safety in R/R myeloma, with ultra-fast manufacturing and strong early durability.

Subcutaneous cevostamab demonstrated activity and safety in patients with multiple myeloma who had received a median of 5 prior lines of therapy.

Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.

Gintemetostat demonstrates efficacy and safety in heavily pretreated multiple myeloma patients, paving the way for future combination therapies.

KRd improved PFS, deepened responses, and led to higher MRD negativity vs VRd in newly diagnosed multiple myeloma.

In the CARTITUDE-4 trial, 80.5% of patients with standard-risk multiple myeloma were progression-free at 2.5 years after receiving cilta-cel.

Elranatamab plus iberdomide showed a 95.5% response rate in patients with BCMA-naive relapsed/refractory myeloma per early MagnetisMM-30 data.

Administering cilta-cel earlier in treatment improves clinical outcomes, with superior PFS and OS rates compared to later intervention.

A look at the top multiple myeloma abstracts set to be presented at the 2025 ASH Annual Meeting.

Larry Anderson, MD, PhD, FACP, discusses data from AURIGA showing that daratumumab plus lenalidomide is a favorable maintenance regimen in multiple myeloma.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Peter Voorhees, MD, discusses the FDA approval of daratumumab for patients with high-risk smoldering multiple myeloma.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.

Joshua Richter, MD, discusses the evaluation of the FcRH5 x CD3 bispecific antibody in multiple myeloma.

Marc S. Raab, MD, discusses evaluating teclistamab–based induction regimens in patients with newly diagnosed multiple myeloma

Andrew Yee, MD, discusses data for a modified four-drug regimen studied in older patients with newly diagnosed multiple myeloma.

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, prostate cancer, and multiple myeloma.